Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2015 Earnings Results

Arrowhead Pharmaceuticals Beats on EPS, Stock Down 0.17%

Arrowhead Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock reacted slightly down by 0.17%, indicating that investors may have been looking for more concrete revenue figures or guidance. The lack of revenue data and forward guidance may have contributed to the muted stock reaction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.27	N/A	+29.87%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed a cautious optimism about their future projects. They acknowledged the competitive landscape but remain focused on their strategic goals.

Management highlighted progress in their pipeline despite the ongoing challenges.

They emphasized their commitment to innovation and long-term growth.

Arrowhead Pharmaceuticals Beats on EPS, Stock Down 0.17%

Key numbers

Management commentary

Arrowhead Pharmaceuticals, Inc.

More earnings this week

Arrowhead Pharmaceuticals Beats on EPS, Stock Down 0.17%

Key numbers

Management commentary